FI903996A0 - Mutanter av humant interleukin-3. - Google Patents

Mutanter av humant interleukin-3.

Info

Publication number
FI903996A0
FI903996A0 FI903996A FI903996A FI903996A0 FI 903996 A0 FI903996 A0 FI 903996A0 FI 903996 A FI903996 A FI 903996A FI 903996 A FI903996 A FI 903996A FI 903996 A0 FI903996 A0 FI 903996A0
Authority
FI
Finland
Prior art keywords
deletion
residues
ala84
cys84
cys16
Prior art date
Application number
FI903996A
Other languages
English (en)
Other versions
FI105192B (fi
Inventor
Lambertus Christiaan Dorssens
Leen Robert Willem Van
Original Assignee
Gist Brocades Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26121243&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI903996(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gist Brocades Nv filed Critical Gist Brocades Nv
Publication of FI903996A0 publication Critical patent/FI903996A0/fi
Application granted granted Critical
Publication of FI105192B publication Critical patent/FI105192B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5403—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI903996A 1989-08-14 1990-08-13 Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi FI105192B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP89202082 1989-08-14
EP89202082 1989-08-14
EP89202331 1989-09-14
EP89202331 1989-09-14

Publications (2)

Publication Number Publication Date
FI903996A0 true FI903996A0 (fi) 1990-08-13
FI105192B FI105192B (fi) 2000-06-30

Family

ID=26121243

Family Applications (1)

Application Number Title Priority Date Filing Date
FI903996A FI105192B (fi) 1989-08-14 1990-08-13 Menetelmä ihmisen interleukiini-3:n mutanttien aikaansaamiseksi

Country Status (17)

Country Link
EP (2) EP0810285A3 (fi)
JP (1) JP3192416B2 (fi)
AT (1) ATE154638T1 (fi)
AU (1) AU636641B2 (fi)
CA (1) CA2023246C (fi)
DD (1) DD301724A9 (fi)
DE (1) DE69030937T2 (fi)
DK (1) DK0413383T3 (fi)
ES (1) ES2106017T3 (fi)
FI (1) FI105192B (fi)
GR (1) GR3024679T3 (fi)
HU (1) HUT54411A (fi)
IE (2) IE980055A1 (fi)
IL (1) IL95350A0 (fi)
NO (1) NO301481B1 (fi)
NZ (1) NZ234869A (fi)
PT (1) PT94992B (fi)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU668364B2 (en) * 1991-10-07 1996-05-02 Medvet Science Pty. Ltd. Human IL-3 variants
US6361977B1 (en) * 1992-11-24 2002-03-26 S. Christopher Bauer Methods of using multivariant IL-3 hematopoiesis fusion protein
US5604116A (en) 1992-11-24 1997-02-18 G. D. Searle & Co. Interleukin-3 (IL-3) multiple mutation polypeptides, recombinant production of the same, and corresponding therapeutic methods
US6361976B1 (en) 1992-11-24 2002-03-26 S. Christopher Bauer Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
US5772992A (en) * 1992-11-24 1998-06-30 G.D. Searle & Co. Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
US6413509B1 (en) 1992-11-24 2002-07-02 S. Christopher Bauer Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
US5738849A (en) * 1992-11-24 1998-04-14 G. D. Searle & Co. Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
US6153183A (en) * 1992-11-24 2000-11-28 G. D. Searle & Company Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
US6403076B1 (en) 1992-11-24 2002-06-11 S. Christopher Bauer Compositions for increasing hematopoiesis with interleukin-3 mutants
US6057133A (en) * 1992-11-24 2000-05-02 G. D. Searle Multivariant human IL-3 fusion proteins and their recombinant production
US5501962A (en) * 1993-06-21 1996-03-26 G. D. Searle & Co. Interleuken-3 (IL-3) human/murine hybrid polypeptides and recombinant production of the same
SG52238A1 (en) * 1993-07-28 1998-09-28 Medvet Science Pty Ltd Haemopoietic growth factor antagonists
US6465616B1 (en) 1994-04-08 2002-10-15 Bresagen Limited Interleukin-5 antagonist
US6017523A (en) * 1995-06-06 2000-01-25 G.D. Searle & Co. Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides
US6270758B1 (en) 1998-10-08 2001-08-07 Duke University Substantially non-toxic biologically active mucosal adjuvants in vertebrate subjects
JP4735670B2 (ja) * 2008-06-11 2011-07-27 富士ゼロックス株式会社 プリント基板および画像処理装置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR871029B (en) * 1986-07-14 1987-11-02 Genetics Inst Novel osteoinductive factors
IE81129B1 (en) 1986-12-16 2000-03-22 Gist Brocades Nv Molecular cloning and expression of human IL-3
EP0275598B1 (en) * 1986-12-16 1998-01-07 Gist-Brocades N.V. Molecular cloning and expression of human IL-3
EP0342206A4 (en) * 1987-01-20 1990-09-19 Immunex Corporation Human interleukin-3 proteins
US4743264A (en) * 1987-02-05 1988-05-10 Sherva Parker Carole J External prothesis with magnetic field
OA09736A (en) * 1987-02-18 1993-11-30 Schering Biotech Corp "Human interleukin-3 and muteins thereof".

Also Published As

Publication number Publication date
PT94992A (pt) 1991-04-18
IE902921A1 (en) 1991-02-27
IL95350A0 (en) 1991-06-30
PT94992B (pt) 1997-09-30
JPH0420295A (ja) 1992-01-23
AU636641B2 (en) 1993-05-06
DE69030937T2 (de) 1997-10-09
ATE154638T1 (de) 1997-07-15
NO301481B1 (no) 1997-11-03
NO903544L (no) 1991-02-15
EP0413383B1 (en) 1997-06-18
EP0810285A2 (en) 1997-12-03
GR3024679T3 (en) 1997-12-31
ES2106017T3 (es) 1997-11-01
IE980055A1 (en) 2000-02-23
CA2023246C (en) 2002-02-19
EP0413383A1 (en) 1991-02-20
DE69030937D1 (de) 1997-07-24
JP3192416B2 (ja) 2001-07-30
HUT54411A (en) 1991-02-28
AU6096090A (en) 1991-02-14
DD301724A9 (de) 1993-08-12
NO903544D0 (no) 1990-08-13
NZ234869A (en) 1991-12-23
FI105192B (fi) 2000-06-30
CA2023246A1 (en) 1991-02-15
EP0810285A3 (en) 1998-07-08
DK0413383T3 (da) 1997-07-07

Similar Documents

Publication Publication Date Title
FI903996A0 (fi) Mutanter av humant interleukin-3.
KR890003802A (ko) 재조합 dna 기술에 의해 제조된 소의 췌장 트립신 억제제, 그 제조 방법, 발현 벡터 및 재조합 숙주 및 그의 제약적 용도
DK0672145T3 (da) Interleukin-3-(IL-3)-polypeptider med flere mutationer
CN1294596A (zh) 修饰蛋白的免疫原性
GB2246783A (en) Fusion proteins containing n-terminal fragments of human serum albumin
AU7565991A (en) Variant cd44 surface proteins, dna sequences coding them, antibodies against these proteins and their use in diagnosis and therapy
RU93045577A (ru) Слитные полипептиды
HUT69169A (en) T-cell-suppressive peptide fragments of human myelin basic protein (hmbp) and pharmaceutical compositions containing them
Bornstein et al. The comparative biochemistry of collagen: The structure of rabbit skin collagen and its relevance to immunochemical studies of collagen
CA2076320A1 (en) Process for producing peptide
Herzbeck et al. Functional and Molecular Characterization of a Monoclonal Antibody against the 165–186 Peptide of Human 1β
NO20011263L (no) Moraxella Catarrhalis BASBO34-polypeptider og anvendelser derav
Kamada et al. Preparation of a uveitogenic peptide by chymotryptic digestion of bovine S-antigen.
Gilbert The expression of human prolactin in Escherichia coli.
KR850002285A (ko) 면역 인터페론의 제조방법
FI961398A (fi) Menetelmä terapeuttisesti käyttökelpoisen peptidin valmistamiseksi
WO1994025594A3 (en) Cloning, expression and vaccine composition corresponding to a peptide antigen of toxoplasma gondii
IE83364B1 (en) Anti-lymphotoxin antibody, its production and use

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: DSM N.V.

MM Patent lapsed

Owner name: DSM N.V.